> The Global Rethinkers > Life sciences innovation
Life sciences innovation
The life sciences and pharmaceutical industries have incredible potential for the future of humankind. We work with many leading figures, and our lawyers are at the cutting edge in supporting our clients.
![](/getattachment/16e16e46-acec-4049-af68-845f2fec7474/wi3256_rethinkers_1_927x500px.jpg)
Dr Bea Bakshi
Super-charging the fight against cancer, Dr Bea Bakshi set up C the Signs to use the power of data to diagnose cancer at its earliest stages, when it can be treated more successfully. Working on the frontline in UK hospitals, Bea repeatedly saw the heart-breaking impact of late diagnosis. In our FT interview series, Bea talks candidly about her experience and how, alongside co-founder Dr Miles Payling, they are helping patients beat cancer.FT interview | Bea Bakshi
![doctor](/getmedia/a4d55741-7e00-403b-895f-7727a6238b02/GettyImages-1150303542-342x213.png?width=342&height=213&ext=.png)
Partnering for success: charities at the forefront of scientific innovation
Find Out More![](/Withers/media/Withers/insights/heroes/Pharmaceuticals_gi-549594217-1.jpg?ext=jpg)
The new Charities Bill: endowment changes and opportunities in science innovation
Find Out More![trees growing in a vertical farm](/getmedia/ec9c692b-17f2-4416-b6b9-95badb516f9c/vertical-farm-1152223952.jpg?width=951&height=634&ext=.jpg)
Can agritech really transform the future of food?
Find Out MoreClients include:
![Alnylam Pharmaceuticals logo](/getattachment/bb3ffb4b-4204-407d-9f45-d74249371b9f/Alnylam-Pharmaceuticals_394x253px.jpg)
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing RNA interference therapeutics that 'silences' Messenger RNAs implicated in the cause of diseases. Alnylam delivered the world's first approved RNAi therapeutic treatment in 2018 and has developed three other first-in-class RNAi-based medicines.![Omega Therapeutics logo](/getattachment/b20113ae-50d8-4bb5-af1b-b9a369bc5249/Omega-Therapeutics_394x253px.jpg)
Omega Therapeutics
Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines designed to controllably modulate gene expression to treat or cure diseases.![Fulcrum Therapeutics logo](/getattachment/773bce9a-12d7-4a4d-9860-fd5543206a05/Fulcrum-Therapeutics_394x253px.jpg)
Fulcrum Therapeutics
Fulcrum Therapeutics specialises in developing treatments for genetic diseases that are largely overlooked by mainstream medicine. By adapting gene expression, disorders can be treated at their root cause.![Medovate logo](/getattachment/d559bdc0-9de5-45e8-848e-8b724cb19e55/Medovate_394x253px.jpg)
Medovate
Medovate works collaboratively with clinical innovators and the NHS to develop, manufacture and bring to market new medical devices to improve patient safety and care.![Kynos Therapeutics logo](/getattachment/634fa66e-db3d-459c-902f-4e64773bb6d1/Kynos-Therapeutics_394x253px.jpg)
Kynos Therapeutics
Kynos Therapeutics is developing an innovative portfolio of first-in-class medicines where there is an unmet medical need for new therapies. Their medicines block the action of KMO - a key enzyme at the interface of inflammation, immunity and metabolism.![Global Access Dx (GADx) logo](/getattachment/2609768a-691b-4404-a2b4-b3261e8244a5/GADx_394x253px.jpg)
Global Access Dx (GADx)
GADx is a leading developer and manufacturer of advanced lateral flow and rapid diagnostic technologies. Leveraging their core technology platforms, they work with governments and international organisations, reinvesting their profits to deliver high quality and affordable diagnostics.Our team
![Thomas Meyers](/getmedia/ba4fe207-c244-4e9b-80fd-4c8e750d44ca/TomMeyersTertiary.png?width=485&height=485&ext=.png)
Thomas Meyers
Partner | Boston
![Zachary D. Hyde](/getmedia/1f2a5336-a528-42c7-8af3-64f7c2e15004/ZackHydeTertiary.png?width=485&height=485&ext=.png)
Zachary D. Hyde
Partner | Boston
![Christopher Cowles, Ph.D.](/Withers/media/Withers/person-pages/listing-images/Chris%20Cowles_TERTIARY.jpg?ext=jpg)
Christopher Cowles, Ph.D.
Partner | Boston
![Susanna Stanfield](/Withers/media/Withers/person-pages/listing-images/IMGL0460-EditSSD,%20Susanna%20Stanfield_TERTIARY.jpg?ext=jpg)
Susanna Stanfield
Partner | Cambridge
![Richard Penfold](/Withers/media/Withers/person-pages/listing-images/IMGL0229-EditRichard%20Penfold,%20RIP_TERTIARY.jpg?ext=jpg)
Richard Penfold
Partner | London
![Richard B. Emmons](/Withers/media/Withers/person-pages/listing-images/Richard%20Emmons_TERTIARY-2.jpg?ext=jpg)
Richard B. Emmons
Partner | Boston
![John Serio](/Withers/media/Withers/person-pages/listing-images/John%20Serio_TERTIARY.jpg?ext=jpg)
John Serio
Partner | Boston
![Jonathan Kok](/Withers/media/Withers/person-pages/listing-images/Johnathan%20Kok_outdoor%201Jonathan%20Kok,%20JQK_TERTIARY.jpg?ext=jpg)
Jonathan Kok
Partner | Singapore
![James Shaw](/Withers/media/Withers/person-pages/listing-images/IMGL0046J9S,%20James%20Shaw_TERTIARY.jpg?ext=jpg)
James Shaw
Partner | London
The Global Rethinkers
We're getting behind some of the founders and innovators who are changing our world. Check out our hub to find out more.